Market Research Logo

Malignant Melanoma: Update Bulletin [April 2016]

Malignant Melanoma: Update Bulletin [April 2016]

Introduction

Gain new KOL insights on the latest events happening in Malignant melanoma (MM): expanded indication label for Bristol-Myers Squibb’s Opdivo plus Yervoy regimen for metastatic melanoma patients regardless of BRAF status; Philogen’s pivotal Phase III trials for Darleukin and Fibromun in patients with stage IIIB/C melanoma and the prospects of Provectus Biopharmaceuticals’ PV-10 in Phase III trial are also discussed.

  • Will Opdivo plus Yervoy combination therapy use increase significantly following BRAF V600 (wild-type & mutation-positive) label expansion?
  • Which patient subsets do KOLs think will benefit most from Opdivo plus Yervoy combination?
  • What are KOLs expecting from the two year survival data in CheckMate 069?
  • How successful do KOLs think Philogen’s Darleukin and Fibromun immunocytokines will be in melanoma?
  • What safety concerns do KOLs have with Darleukin/Fibromun and which combinations could hold the key to their success?
  • What are the prospects of Provectus’ PV-10 and how do KOLs view the inclusion of Imlygic as a comparator in Phase III study?


Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report